Overview
Management Team
Board of Directors
Clinical Advisory Board
IRC 6045B
Picoplatin Overview
Picoplatin Value
Proposition
Colorectal Cancer
Prostate Cancer
Ovarian Cancer
Small Cell Lung Cancer
Overview
Annual Repoort
SEC Filings
Stock Information
News Releases
Event Calendar
Presentations and
Publications
Shareholder Services
Corporate Governance
Locations
Corporate
Communications &
Investor Relations
Business Development
P
oniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer.
NEWS
IRC 6045B Disclosure Documents
- 1/17/2012
Poniard Pharmaceuticals Common Stock to Be Delisted From Nasdaq Stock Market, Intention to List on OTC Bulletin Board
- 1/3/2012
Poniard Pharmaceuticals and Allozyne Terminate Planned Merger
- 12/22/2011
Poniard Pharmaceuticals Announces Shareholders Approve Merger With ALLOZYN
- 11/21/2011
EVENTS & PRESENTATIONS
Details on upcoming events are not yet available.
About Poniard
|
Picoplatin Overview & Market Opportunities
|
Investors
|
Contact Us
© 2011 Poniard Pharmaceuticals.
Corporate Governance
|
Site Users Guide
